INS and polycystic ovary syndrome: In women with polycystic ovary syndrome, myo-inositol has been documented to improve systemic metabolic parameters such as lowering plasma triglyceride and low-density lipoprotein concentrations, while increasing high-density lipoprotein, improving insulin sensitivity (Minozzi et al., 2013), and decreasing hemoglobin A1C (Pintaudi et al., 2016).